iqlik
-
Alzheimer’s & Dementia Care
U.S. FDA Approves Leqembi Iqlik Subcutaneous Autoinjector for Early Alzheimer’s Disease Maintenance Dosing
The U.S. Food and Drug Administration (FDA) has announced the approval of Leqembi Iqlik (lecanemab-irmb), an innovative under-the-skin autoinjector formulation…
Read More » -
Alzheimer’s & Dementia Care
FDA Reviews Expanded Approval for Leqembi Iqlik: Subcutaneous Option for Early Alzheimer’s Treatment Initiation
The U.S. Food and Drug Administration (FDA) is currently reviewing a supplemental Biologics License Application (sBLA) seeking expanded approval for…
Read More »
